Jump to content

Ethacizine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 04:09, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ethacizine
Clinical data
Trade namesEthacizin
AHFS/Drugs.comInternational Drug Names
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability~40% (oral)[1]
Protein binding90%
MetabolismExtensive hepatic
Elimination half-life2.5 hours
Identifiers
  • ethyl N-[10-[3-(diethylamino)propanoyl]phenothiazin-2-yl]carbamate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H27N3O3S
Molar mass413.54 g·mol−1
3D model (JSmol)
  • CCN(CC)CCC(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)NC(=O)OCC
  • InChI=1S/C22H27N3O3S/c1-4-24(5-2)14-13-21(26)25-17-9-7-8-10-19(17)29-20-12-11-16(15-18(20)25)23-22(27)28-6-3/h7-12,15H,4-6,13-14H2,1-3H3,(H,23,27) checkY
  • Key:PQXGNJKJMFUPPM-UHFFFAOYSA-N checkY

Ethacizine (ethacyzine) is a class Ic antiarrhythmic agent, related to moracizine. It is used in Russia and some other CIS countries for the treatment of severe and/or refractory ventricular and supraventricular arrhythmias, especially those accompanied by organic heart disease. It is also indicated as a treatment of refractory tachycardia associated with Wolff–Parkinson–White syndrome.[1]

It is manufactured under the brand name Ethacizin (Этацизин) by Olainfarm.[2]

References

  1. ^ a b "Этацизин (Ethacyzin) Prescribing Information. VIDAL Drug Compendium" (in Russian). Retrieved 5 February 2014.
  2. ^ "Этацизин—4DOKTOR.RU Drug Information Handbook" (in Russian). Retrieved 5 February 2014.